ProCE Banner Activity

It Takes a Village: How Clinical Care Pathways Can Standardize NAFLD Patient Management Across Medical Disciplines

Clinical Thought
Those who treat patients with type 2 diabetes may encounter nonalcoholic fatty liver disease. See an expert&rsquo s summary of guideline-recommended management and how we can better care for these patients.

Released: January 04, 2023

Expiration: January 03, 2024

No longer available for credit.

Share

Faculty

Rohit Loomba

Rohit Loomba, MD, MHSc

Director, NAFLD Research Center
Professor of Medicine
Director of Hepatology
University of California at San Diego
La Jolla, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Novo Nordisk Inc

Faculty Disclosure

Primary Author

Rohit Loomba, MD, MHSc

Director, NAFLD Research Center
Professor of Medicine
Director of Hepatology
University of California at San Diego
La Jolla, California

Rohit Loomba, MD, MHSc: consultant: 89bio, Aardvark Therapeutics, Altimmune, Anylam/Regeneron, Amgen, Arrowhead, AstraZeneca, Bristol-Myers Squibb, CohBar, Galmed, Gilead Sciences, Glympse Bio, HighTide, Inipharm, Intercept, Inventiva, Ionis, Janssen, Lilly, Madrigal, Merck, Metacrine, NGM Biopharmaceuticals, Novartis, Novo Nordisk, Pfizer, Sagimet, Theratechnologies, Terns, Viking Therapeutics; researcher: Arrowhead, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Galectin Therapeutics, Galmed, Gilead Sciences, Hanmi, Intercept, Inventiva, Ionis, Janssen, Lilly, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Sonic Incytes, Terns Pharmaceuticals; cofounder: LipoNexus.